In March 2020, LLS made an equity investment in Kymera Therapeutics to "Support Key Studies with IRAK4 and STAT3 Protein Degraders for Future Development in Hematological Patients."
Kymera received this strategic investment from LLS TAP to advance work in an emerging approach to cancer therapy, called “targeted protein degradation.” Whereas most targeted therapies inhibit or inactivate the proteins or genes that drive the cancer, targeted protein degradation harnesses the body’s natural system of ridding itself of unwanted, “old” or “broken” components of cells.
Kymera Therapeutics is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.
Kymera recently presented its first preclinical data on this approach, showing robust antitumor activity in lymphomas with the MYD88-mutation, which constitute approximately one-quarter of all diffuse large B-cell lymphoma (DLBCL). These new findings complement previous data showing that Kymera’s degraders of STAT3, an important protein in blood cancers and solid tumors, are capable of driving tumor regression in animal models of STAT3-dependent blood-based cancers.
A clinical trial of KT-333, a STAT3 protein degrader, is currently enrolling NHL patients (NCT05225584).
A clinical trial of KT-413, a dual degrader of IRAK4 and IMiD substrates, is currently enrolling DLBCL patients (NCT05233033).
For more information about Kymera, visit www.kymeratx.com.
- July 15, 2022 - recently dosed the first patients in separate Phase 1 clinical trials evaluating the STAT3 degrader KT-333 and the IRAKIMiD degrader KT-413. The KT-333 trial includes patients with relapsed/refractory liquid and solid tumors, including T cell lymphomas and leukemia, and the KT-413 study is enrolling patients with relapsed/refractory B cell lymphomas, including MYD88-mutant diffuse large B cell lymphoma (DLBCL).
- June 1, 2022 - announced that the FDA has granted orphan drug designation to KT-333 for the treatment of Peripheral T-cell Lymphoma (PTCL).
- December 13, 2021 - announced the company presented new preclinical data for its STAT3 degraders, including its first-in-class KT-333 STAT3 degrader, at the virtual 63rd American Society of Hematology (ASH) Annual Meeting taking place from December 11 – 14, 2021 in Atlanta, GA and virtually.
- November 30, 2021 - announced the clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for its IRAKIMiD degrader, KT-413.
- November 10, 2021 - announced clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for its first-in-class STAT3 degrader, KT-333, now poised to enter the clinic in patients with liquid and solid tumors before year end.
- July 06, 2021 - announced the closing of its upsized underwritten public offering at a public offering price of $47.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $257.0 million.